医学
改良兰金量表
冲程(发动机)
基底动脉
闭塞
血管成形术
格拉斯哥昏迷指数
单变量分析
麻醉
外科
内科学
缺血
多元分析
缺血性中风
机械工程
工程类
作者
Rawad Abbas,Ching-Jen Chen,Elias Atallah,Kareem El Naamani,Abdelaziz Amllay,Georgios S Sioutas,M. Reid Gooch,Nabeel Herial,Pascal Jabbour,Robert H. Rosenwasser,Stavropoula Tjoumakaris
出处
期刊:Neurosurgery
[Oxford University Press]
日期:2022-12-01
卷期号:92 (4): 772-778
标识
DOI:10.1227/neu.0000000000002261
摘要
Acute basilar artery occlusion accounts for 1% of all ischemic strokes but often leads to devastating neurological injury and mortality. Many institutions still opt for best medical therapy for these patients; however, there is increasing evidence that mechanical thrombectomy (MT) for these patients leads to better outcomes.To assess the safety and efficacy of MT for patients presenting with acute basilar artery occlusion (BAO).This study was a retrospective chart review of a prospectively maintained database for patients with acute BAO treated with MT from January 2014 through March 2022.Our study included a total of 74 patients. The mean age was 62.7 years, and 55.4% were male. The most common comorbidity was hypertension (73%). The mean door to puncture time was 75 minutes, and the mean procedure time was 54 minutes. 86.5% of patients had a good modified treatment in cerebral ischemia score (≥2b). There were 4 patients who had procedural complications and 3 who had symptomatic intracerebral hemorrhage. At 90 days, 62.5% of patients had a modified Rankin Scale, 0 to 3. The mortality rate was 32.4% and 2% during hospital admission and 90 days, respectively. On univariate analysis, adjunctive angioplasty/stenting and higher presenting National Institutes of Health Stroke Scale score were associated with modified Rankin Scale 4 to 6 at 90 days ( P -value, .03 and <.001, respectively). Shorter procedure time was associated with modified treatment in cerebral ischemia score ≥ 2b ( P -value, .0015).Our findings showed that MT is safe and effective for patients presenting with acute BAO and is in conjunction with previous literature. The results from upcoming trials should hopefully establish MT as gold standard for these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI